Vanguard Group Inc. raised its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 26.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,494,347 shares of the biopharmaceutical company’s stock after buying an additional 521,669 shares during the period. Vanguard Group Inc. owned 0.06% of Vanda Pharmaceuticals worth $34,920,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the stock. Virginia Retirement Systems ET AL acquired a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at about $193,000. Capital Fund Management S.A. acquired a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at about $195,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at about $196,000. AQR Capital Management LLC acquired a new stake in shares of Vanda Pharmaceuticals during the fourth quarter valued at about $223,000. Finally, Algert Global LLC raised its stake in shares of Vanda Pharmaceuticals by 11.8% in the first quarter. Algert Global LLC now owns 18,223 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 1,927 shares in the last quarter. 90.84% of the stock is owned by hedge funds and other institutional investors.

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) traded down 0.93% on Tuesday, reaching $15.95. The company’s stock had a trading volume of 19,870 shares. Vanda Pharmaceuticals Inc. has a 12-month low of $11.58 and a 12-month high of $18.00. The company’s 50-day moving average is $16.17 and its 200 day moving average is $14.74. The company’s market capitalization is $715.49 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.18. The business had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.01 earnings per share. Equities analysts anticipate that Vanda Pharmaceuticals Inc. will post ($0.52) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Vanda Pharmaceuticals Inc. (VNDA) Shares Bought by Vanguard Group Inc.” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/vanda-pharmaceuticals-inc-vnda-shares-bought-by-vanguard-group-inc/1491601.html.

VNDA has been the subject of several research analyst reports. Piper Jaffray Companies set a $23.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. HC Wainwright set a $18.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Oppenheimer Holdings, Inc. set a $21.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Jefferies Group LLC reaffirmed a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Thursday, May 25th. Finally, TheStreet raised Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Friday, May 12th. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $21.33.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.